Domestic new drug research and development has entered a period of rapid development, and pharmaceutical companies have set off a "financing fever"

 Domestic new drug research and development has ushered in a period of rapid development.
With the growth of innovative drug companies, financing events in the pharmaceutical industry have also continued to appear
.
The author was informed that a number of pharmaceutical companies recently promoted the completion of huge financing
.
Biaoxin Biotech received over 100 million yuan of Pre-A round of financing
.
This round of financing will be used for its core project GT919 clinical phase I research, as well as clinical application research and subsequent pipeline development for projects such as tumors and autoimmune diseases
.
Targeted protein degradation technology is a very innovative and challenging cutting-edge technology.
It only needs catalytic activity and does not require high-affinity binding pockets, so that it can target a variety of non-drugable targets and overcome the problems of small molecule drugs.
A variety of drug resistance, and can play a role in a lower dose, so that this technology has become the darling of the small molecule new drug research and development market in recent years
.
Biaoxin Biotech stated that it will continue to accelerate the clinical registration process of its products, enrich its technical reserves, and further promote the development of protein-degrading drugs in China
.
Jiabei Pharmaceutical announced the completion of a round of financing of nearly 100 million yuan.
Ningbo Jiabei Pharmaceutical Technology Co.
, Ltd.
(abbreviated as: Jiabei Pharmaceutical) announced that it has completed a round of financing of nearly 100 million yuan.
This round of funds will be used to continue to strengthen Jiabei's biological industry in Ningbo The construction of the cGMP production workshop in the park will further accelerate the expansion of Jiabei Pharmaceutical's R&D technical team
.
According to public information, Jiabei Medicine focuses on the development of biopharmaceutical technology and CDMO technical services.
The company has completed the establishment of service platforms for antibody drug screening and discovery, production process development, and antibody drug production, with various technical levels at the forefront
.
Quanrong Pharmaceutical Technology completed tens of millions of yuan in Series B financing Quanrong Pharmaceutical Technology recently announced the completion of tens of millions of yuan in Series B financing
.
Regarding this round of financing, Quanrong Pharmaceutical Technology stated that it will continue to provide better innovative solutions for digital intelligence clinical trials, making clinical trials more efficient, transparent and smarter
.
Regarding this round of investment, the couplet health fund said: the clinical trial industry is troubled by information isolation and opacity, and digital intelligence is a major trend
.
Chuanrong Pharmaceutical has integrated abundant clinical resources, and its product design respects the clinic, which will effectively promote the digital intelligence of clinical trials
.
Coupled Health Fund is willing to work with the company to integrate resources, empower the industry, and improve the overall efficiency and quality of the clinical trial industry
.
Huimei Capital stated: The efficiency and quality of clinical research are of the utmost importance in medical clinical innovation
.
Through the rapid start-up of the development and research center, research drug management, genetic office application filing, and subject visit management and other system subdivision service modules, Chuanrong Pharmaceutical Technology can greatly improve the efficiency of clinical trial execution and improve project quality, thereby giving Energy medical innovation companies accelerate the entry of medical innovation products into clinical use, and ultimately benefit the majority of patients by solving unmet clinical needs
.
Huimei Capital therefore firmly chooses to join hands with Chuanrong Pharmaceutical Technology, and looks forward to further promoting China's medical clinical innovation
.
Hanhai New Enzyme has completed nearly 800 million yuan in Series C financing of biomedical special enzyme industrialization company Wuhan Hanhai New Enzyme Biotechnology Co.
, Ltd.
(referred to as "Hanhai New Enzyme") announced that it has completed nearly 800 million yuan after this round of financing, Hanhai New Enzyme will accelerate the construction of a special enzyme creation platform, build a biomedical industry, realize the import substitution of core enzyme materials in China's biomedical field, and help and join hands with biomedical companies to go global
.
Zhimeng Pharmaceutical completes 350 million yuan in round B financing.
Recently, Zhimeng Pharmaceutical, a chronic liver disease treatment drug developer, announced that it has completed 350 million yuan in round B financing.
The raised funds will be mainly used for its chemical structure of hepatitis B virus nucleocapsid inhibitor ZM- The phase II clinical study of H1505R, the immunomodulator for the treatment of hepatitis B and the phase I clinical study of the KCNQ2/3 potassium channel opener for the treatment of epilepsy, pain and depression
.
The core project of Zhimeng Medicine, ZM-H1505R, is a new hepatitis B virus nucleocapsid inhibitor.
Phase Ia clinical data show that ZM-H1505R has excellent safety and pharmacokinetic properties
.
Currently undergoing phase Ib clinical research in patients with chronic hepatitis B
.
In addition, a number of self-researched projects of Zhimeng Medicine are undergoing clinical applications, including an immunomodulator project for the treatment of hepatitis B, and a KCNQ2/3 potassium channel opener project for the treatment of epilepsy, pain, and depression.
It is expected to be next year Entered clinical research at the beginning
.